Show main content
A collaborative effort by Helmholtz Munich, the German Diabetes Center, and the German Center for Diabetes Research

What concomitant and secondary diseases can be associated with obesity?

Scientific support: Prof. Dr. Reiner Jumpertz-von Schwartzenberg

Overweight and obesity can lead to many health problems that may severely impair quality of life and even shorten life expectancy. There is hardly an organ or organ system that cannot be affected by diseases associated with obesity. Experts therefore also speak of these diseases as being obesity-associated.

The risk of developing obesity-associated concomitant and secondary diseases increases with the severity and duration of obesity. Genetic predisposition also plays a role. Besides improving quality of life, losing weight has a positive effect on the risk of developing the disease, as well as on most existing secondary diseases and the psyche.



1. How high is the risk of developing obesity-associated secondary diseases?

The personal risk of developing obesity-associated secondary diseases depends on the individual’s genetic predisposition. It increases the longer obesity exists and the more pronounced it is. Apart from the classic classification of obesity according to the body mass index, or BMI for short (body weight/body size in m2), the distribution and function of the additional fatty tissue is particularly decisive for the risk of secondary diseases. People with obesity and an increased content of fat in the liver or abdomen (also known as visceral fat) have an above-average risk of secondary diseases. Some experts have recently started referring to this as clinical obesity.

There are also complex correlations between secondary diseases that are based on similar physiological processes. These diseases can cause and reinforce each other, for example type 2 diabetes and fatty liver disease.

 

According to a report by the World Health Organization (WHO), people with obesity have a more than 3-fold increased risk of developing metabolic diseases such as type 2 diabetes and/or a fatty liver compared to people of normal weight. In addition, obesity is often associated with breathing disorders during sleep, known as sleep apnea syndrome.

People with obesity have a 2 to 3 times higher risk of also developing high blood pressure and other cardiovascular diseases as well as lipometabolic disorders. If high blood pressure, increased blood sugar levels and elevated blood lipid levels are present in combination with obesity, the risk of further illnesses or cardiovascular events such as heart attack and stroke increases.

People with obesity have a 1 to 2 times higher risk of tumor, gastrointestinal, kidney and lung diseases. In addition, obesity is associated with hormonal disorders in women and men, for example polycystic ovary syndrome or infertility.

Obesity and the desire to have children:

Hormonal changes can make it more difficult for women with obesity to get pregnant. Women who are obese and want to have children are therefore advised to reduce their body weight as much as possible. Obesity is also associated with an increased risk of complications during pregnancy. These include, for example, pre-eclampsia, gestational diabetes or thrombosis. Newborns have an increased risk of reaching a high birth weight, which in turn is associated with an increased risk of birth complications as well as overweight and obesity during childhood and adolescence. Malformations in the newborn or miscarriages also occur more frequently.

In men, obesity can lead to infertility. Lower testosterone levels can impair sperm production and quality.

Furthermore, an increased body weight is associated with an increased risk of osteoarthritis in the hip or knee and leads more frequently to back problems. Older people in particular are at an increased risk of accidents and injuries due to their limited mobility.

People with obesity experience more complications during operations and anesthesia than people of normal weight. On the one hand, this is attributed to technical reasons owing to the increased body weight. On the other hand, metabolic conditions, existing cardiovascular stress and pre-existing organ damage or a diminished effect of medication can increase the risk in people with obesity.

Good to know:

However, an increased risk alone does not mean that a person with obesity will actually develop these diseases. It only means that these diseases occur statistically more frequently in people with obesity than in people of normal weight. It is important to have your personal situation examined by a doctor in order to be able to assess your own risk of secondary diseases.

In addition to the medical health risks, psychosocial aspects also play an important role in obesity. Obesity still often leads to social exclusion. The consequences can be depressive illnesses and anxiety disorders, reduced participation in social events and diminished self-esteem. Restricted physical mobility can also impair quality of life.

In general: The longer obesity persists and the more pronounced it is, the more difficult it is to treat obesity-associated secondary diseases and obesity itself. In some cases, it is no longer possible to reverse secondary diseases.

Obesity paradox:

While it is undisputed that obesity increases the risk of secondary diseases, some studies have come to the conclusion that older people who are overweight and obese often have a better prognosis for cardiovascular or other serious diseases than people of normal weight. This observation is known as the obesity paradox and is primarily attributed to a higher nonfat body mass and greater energy reserves of people who are overweight. However, studies do not show clear results: For example, the obesity paradox could not be confirmed in studies that are based on body fat distribution instead of the BMI. This underlines the importance of body fat distribution.


2. Why can obesity lead to type 2 diabetes?

Obesity is one of the most important risk factors for type 2 diabetes. Body weight, especially waist circumference, is closely linked to the risk of type 2 diabetes. The duration and severity of the obesity play a decisive role: Each 1 kg/m² that the body mass index (BMI) is higher corresponds to a 25 percent increased risk of type 2 diabetes.

Researchers suspect that obesity promotes the development of insulin resistance due to a persistent lack of exercise, an oversupply of energy- and sugar-rich foods and an altered release of messenger substances from the fatty tissue. In addition, not only the quantity but also the quality of the diet is a key factor in the development of obesity. This applies in particular to abdominal obesity, which is associated with a high risk of concomitant diseases. It has recently been shown that around 70 percent of new cases of type 2 diabetes can be attributed to reduced dietary quality.

Good to know:

Obesity is associated with a more than 3-fold increased risk of type 2 diabetes.

 

Insulin opens the body cells like a key to absorb sugar from the blood. The body cells need sugar to produce energy. In the case of insulin resistance, body cells become less sensitive to the hormone insulin. The sugar can then no longer be absorbed as effectively into the body cells and remains in the blood to a greater extent. The insulin-producing beta cells of the pancreas try to compensate for this by producing more and more insulin. However, this overexertion causes the beta cells to become exhausted, which in turn leads to too little insulin being produced over time. The blood sugar level then rises and type 2 diabetes develops. Around 80 percent of all newly diagnosed cases of type 2 diabetes are associated with overweight.

Find more information about the development of type 2 diabetes here.


3. Obesity and cardiovascular disease

A rising body weight, especially in conjunction with increased abdominal fat, increases the risk of developing cardiovascular disease by a factor of 2 to 3. The visceral fat accumulates around the internal organs in the abdominal cavity. Compared to fat stored under the skin (subcutaneous), visceral fat is much more metabolically active. It can promote the release of pro-inflammatory substances from migrating immune cells and thus trigger chronic inflammation in the body. This can damage the blood vessels and promote arteriosclerosis. As a result, the likelihood of developing high blood pressure, heart failure, cardiac arrhythmia or thromboembolism (blood clots) increases.

One variable to measure visceral fat content is the waist circumference.

Read more about the most common cardiovascular diseases here.


4. Obesity and fatty liver

People with abdominal (visceral) obesity have a more than 3 times higher risk on average to develop fatty liver disease than people of normal weight. If more than 5 in 100 liver cells have stored an excessive amount of fat, this is known as a fatty liver. This clinical picture is also referred to as “metabolic dysfunction-associated steatotic liver disease” (MASLD) in the case of existing obesity.

MASLD promotes insulin resistance and is therefore closely related to the development of type 2 diabetes. Type 2 diabetes can be both a trigger and a secondary disease of a fatty liver. The 2 clinical pictures are mutually dependent.

Find more information on a fatty liver and its relation to type 2 diabetes here.

 

People with a fatty liver have an increased risk of developing liver cirrhosis. Over time, healthy liver tissue is replaced by connective tissue. This impairs liver function and can lead to the development of hepatocellular carcinoma.

People with a BMI of 30 kg/m² or higher, or a BMI of 25 kg/m² or higher with additional metabolic and/or cardiovascular disease, should be examined by a doctor for fatty liver disease using ultrasound and/or laboratory measurements.


5. Obesity and psychosocial consequences

People who are overweight or obese are often judged negatively by society and held solely responsible for their increased body weight. This greatly simplifies the understanding of how obesity develops. It is wrongly assumed that obesity can only be avoided by increasing exercise and reducing calorie intake. More complex correlations such as genetic predisposition and environmental factors as well as the poor long-term feasibility are usually ignored. Due to this stigmatization, affected people are discriminated in many areas of life. Obesity is often a barrier to professional success.

The transfer of the negative social image to one’s own body image is referred to as self-stigma. This further reduces self-esteem and can lead to anxiety disorders and depression. Eating disorders can further intensify obesity or make treatment more difficult.

The stress caused by stigmatization can in turn have an impact on health: Stress is associated with the development of cardiovascular disease, type 2 diabetes and inflammation. In the short term, stress can increase blood pressure and trigger an increased release of cortisol. In the long term, this leads to an increased risk of body weight continuing to rise and obesity persisting or worsening.

Studies show that intensive behavioral therapy can reduce self-stigma and thus improve mental health and quality of life.

 

Behavioral therapy aims at

  • strengthening self-esteem regardless of body weight,
  • breaking negative thought spirals, for example through mindfulness,
  • learning to defend oneself against prejudices by others, and
  • deepening one’s knowledge of the various causes of obesity and thus being able to better assess one’s own responsibility.

Good to know:

Self-help programs can help people to break out of social isolation and approach obesity treatment with more motivation together with like-minded people.

In addition, an unbiased portrayal of people with obesity in the media and more widespread provision of reimbursable weight loss programs – as would actually be required due to the recognition of obesity as a chronic disease – could counteract social stigmatization.


6. Is obesity associated with a shorter life expectancy?

Studies that statistically examine the relationship between body mass index (BMI) and overall mortality show a curve in the shape of the letter “J.” This means that mortality – the number of deaths in a group during a certain period of time – is increased at both ends of the BMI scale. The lowest mortality rate is in the normal weight range (BMI of 18.5 to 24.9 kg/m²).

According to current knowledge, the increased mortality rate among underweight people (BMI less than 18.5 kg/m²) is attributed to pre-existing illnesses. For example, smoking and the associated secondary diseases can play a role. With increasing BMI, mortality increases slowly at first, then faster and faster.

However, in addition to the BMI, body composition and fat distribution must also be taken into account: Abdominal obesity in particular is associated with a high health risk.


7. What can I do to prevent secondary diseases?

The risk of developing obesity-associated concomitant and secondary diseases increases with the severity and duration of obesity. It is therefore important to take countermeasures at an early stage and reduce body weight. This should be done in consultation with a doctor.

Doctors determine the health risk based on the individual overall picture of the person affected. In addition to pure measurements such as BMI and waist circumference, existing diseases such as type 2 diabetes, cardiovascular diseases and orthopedic diseases as well as psychosocial aspects are also taken into account. The possible treatment options can then be discussed together and the appropriate steps towards weight loss can be planned.

A weight reduction of just 3 to 5 percent has a positive effect on existing risk factors and obesity-associated secondary diseases such as cardiovascular disease and type 2 diabetes.

Good to know:

Many organ systems benefit from weight reduction, the risk of obesity-associated secondary diseases decreases and the quality of life increases.

Sources:

Butt, J. H. et al.: Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. In: Eur Heart J, 2023, 44: 1136-1153
Deutsche Adipositas-Gesellschaft et al.: S3-Leitlinie Adipositas - Prävention und Therapie. Version 5.0. 2024
Deutsche Gesellschaft für Gynäkologie und Geburtshilfe et al.: S3-Leitlinie Adipositas und Schwangerschaft. Version 1.2. 2019
Döhner, W.: Das Adipositas-Paradox/Paradigma bei kardiovaskulären Erkrankungen: Fakten und Kommentare. In: Adipositas - Ursachen, Folgeerkrankungen, Therapie, 2021, 15: 13-20
Global BMI Mortality Collaboration et al.: Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. In: Lancet, 2016, 388: 776-786
Guh, D. P. et al.: The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. In: BMC Public Health, 2009, 9: 88
Jayedi, A. et al.: Central fatness and risk of all-cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. In: BMJ, 2020, 370: m3324
Kivimäki, M. et al.: Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. In: Lancet Public Health, 2017, 2: e277-e285
O'Hearn, M. et al.: Incident type 2 diabetes attributable to suboptimal diet in 184 countries. In: Nat Med, 2023, 29: 982-995
Palmeira, L. et al.: Exploring the efficacy of an acceptance, mindfulness-, compassionate-based group intervention for women struggling with their weight (Kg-Free): A randomized controlled trial. In: Appetite, 2017, 112: 107-116
Rubino, F. et al.: Definition and diagnostic criteria of clinical obesity. In: Lancet Diabetes Endocrinol, 2025 (Online ahead of print)
Schienkiewitz, A. et al.: Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. In: Am J Clin Nutr, 2006, 84: 427-433
World Health Organization: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. In: World Health Organ Tech Rep Ser, 2000, 894: 1-253
As of: 17.02.2025